Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

54.78USD
21 Feb 2017
Change (% chg)

$0.19 (+0.35%)
Prev Close
$54.59
Open
$54.41
Day's High
$57.21
Day's Low
$53.41
Volume
26,919,342
Avg. Vol
12,303,925
52-wk High
$77.12
52-wk Low
$46.01

BMY

Chart for BMY

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.06
Market Cap(Mil.): $91,549.98
Shares Outstanding(Mil.): 1,671.23
Dividend: 0.39
Yield (%): 2.85

Financials

  BMY Industry Sector
P/E (TTM): 20.65 28.45 29.35
EPS (TTM): 2.65 -- --
ROI: 18.67 13.47 12.97
ROE: 29.28 14.36 14.11

Fitch Rates Bristol-Myers Squibb's Notes Offering 'A-'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, February 22 (Fitch) Fitch Ratings has assigned an 'A-' rating to Bristol-Myers Squibb Company's (Bristol, BMY) senior unsecured notes offering. Proceeds will be used to partially fund an accelerated share repurchase program (ASR). The Rating Outlook is Stable. KEY RATING DRIVERS --The company maintains decent headroom under the 2.0x gross leverage level Fitch considers appropriate for the 'A-' rating after incorporating th

4:42pm EST

PRESS DIGEST - Wall Street Journal - Feb 22

Feb 22 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

1:44am EST

Icahn buys Bristol-Myers shares, adding to activist pressure

Billionaire investor Carl Icahn has taken a stake in Bristol-Myers Squibb Co and sees the drugmaker as a possible takeover target, according to a report published on Tuesday that sent the company's shares from a loss to more than 2 percent higher.

Feb 21 2017

UPDATE 3-Icahn buys Bristol-Myers shares, adding to activist pressure

Feb 21 Billionaire investor Carl Icahn has taken a stake in Bristol-Myers Squibb Co and sees the drugmaker as a possible takeover target, according to a report published on Tuesday that sent the company's shares from a loss to more than 2 percent higher.

Feb 21 2017

Carl Icahn takes stake in Bristol Myers: WSJ

Activist investor Carl Icahn has taken a stake in Bristol-Myers Squibb Co , the Wall Street Journal reported, citing people familiar with the matter.

Feb 21 2017

Carl Icahn takes stake in Bristol Myers - WSJ

Feb 21 Activist investor Carl Icahn has taken a stake in Bristol-Myers Squibb Co, the Wall Street Journal reported, citing people familiar with the matter.

Feb 21 2017

BRIEF-Bristol-Myers sees restructuring charges between $1.5-$2.0 bln through 2020

* Bristol-Myers Squibb says expects to incur charges through 2020, ranging between $1.5 billion to $2.0 billion in connection with restructuring announced in Oct 2016

Feb 21 2017

Bristol-Myers adds three directors in deal with JANA Partners

Feb 21 Bristol-Myers Squibb Co said on Tuesday it appointed three directors to its board in a deal with JANA Partners LLC, an activist investor holding less than 1 percent of the company's stock.

Feb 21 2017

Bristol-Myers adds three directors in deal with Jana Partners

Feb 21 Bristol-Myers Squibb Co said on Tuesday it appointed three directors to its board in a deal with activist investor Jana Partners LLC.

Feb 21 2017

BRIEF-Bristol-Myers Squibb appoints three new independent directors

* Bristol-Myers Squibb appoints three new independent directors Source text for Eikon: Further company coverage:

Feb 21 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $119.52 -0.14
Pfizer Inc. (PFE.N) $33.59 -0.03
Merck & Co., Inc. (MRK.N) $65.29 -0.19
Sanofi SA (SASY.PA) €80.27 -0.26
AstraZeneca plc (AZN.L) 4,556.00 -6.00
GlaxoSmithKline plc (GSK.L) 1,653.50 +8.00
Eli Lilly and Co (LLY.N) $81.07 +0.71
Roche Holding Ltd. (ROG.S) CHF246.30 -0.20
Roche Holding Ltd. (RO.S) CHF249.90 +0.30

Earnings vs. Estimates